Notice of Intent - Illumina MiSeq i100 series instruments

This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Illumina, Inc.

Acquisition Description:

1. 
   
   
   
   1. The purpose of this acquisition is to purchase two Illumina MiSeq i100 series instruments. These instruments will be used by the NIH HLA Laboratory to produce high resolution HLA typing results for the numerous transplant protocols supported by the laboratory. It will replace the current Illumina MiSeq instruments in the lab that were purchased in 2021 and 2022. The vendor will discontinue service on the current model of the MiSeq. New instruments are required to ensure time to validate these replacements before discontinuation of service. The total dollar value for this order is $139,100.52.
   
   
   2. 
      
      
      
      1. The MiSeq is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run. The MiSeq provides the Lab with the highest HLA typing results possible. The transplant protocols served by the HLA Lab require highest resolution possible to increase the chance of a successful transplant. The HLA Lab currently owns two MiSeq instruments, so the procedures and Quality Control assessments are in place. The order aims to replace the Illumina Miseq – s/n M07700 (property ID is 02223449) and s/n M08636 (property ID is 02268689) that were purchased in 2019 and 2022. Replacement is necessary to ensure proper performance of these instruments prior to discontinuation of service for the current model of the Illumina MiSeq instruments by the vendor.
      
      
      
      
   
   
   
   

The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000836) by 12:00 PM eastern standard time on 11/27/2026 to: valerie.gregorio@nih.gov.

All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.